T cell infiltration and prognosis in HCC patients

Journal of Hepatology

Volumn 45, Issue 2, 2006, Pages 178-181

  Parmiani, Giorgio ^a   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; EDITORIAL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOMA; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

CARCINOMA, HEPATOCELLULAR; CD4-CD8 RATIO; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 33745699330     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.06.005     Document Type: Editorial

References (40)

1. Anthony P.P. Hepatocellular carcinoma: an overview. Histopathology 39 (2001) 109-118
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94 (2001) 153-156
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. Yoo H.Y., Patt C.H., Geschwind J.F., and Thuluvath P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21 (2003) 4329-4335
5. Allgaier H.P., Deibert P., Olschewski M., et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer 79 (1998) 601-605
6. Levy I., and Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50 (2002) 881-885
7. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-700
8. Wada Y., Nakashima O., Kutami R., Yamamoto O., and Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27 (1998) 407-414
9. Zerbini A., Pilli M., Soliani P., Ziegler S., Pelosi G., Orlandini A., et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8 1 cells in patients with hepatocellular carcinoma. J Hepatol 40 (2004) 102-109
10. Shang X.Y., Song Chen H., Zhang H.G., Pang X.W., Qiao H., Peng J.R., et al. The spontaneous CD8_ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10 (2004) 6946-6955
11. Hanke P., Rabe C., Serwe M., Bohm S., Pagenstecher C., Sauerbruch T., et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37 (2002) 949-955
12. Yutani S., Shichijo S., Inoue Y., Kawagoe N., Okuda K., Kurohiji T., et al. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas. Oncol Rep 8 (2001) 369-372
13. Takao Y., Yamada A., Yutani S., Sata M., and Itoh K. Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of including HLA-A2 restricted cytotoxic T lymphocytes is detectable in the majority of HCV-infected individuals without HLA-A2 restriction. Microbiol Immunol 48 (2004) 507-517
14. + cytotoxic T lymphocytes. J Clin Invest 97 (1996) 577-584
15. Unitt E., Marshall A., Gelson W., Rushbrook S.M., Davies S., Vowler S.L., et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 45 (2006) 246-253
16. + regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45 (2006) 254-262
17. Unitt E., Rushbrook S.M., Marshall A., Davies S., Gibbs P., Morris L.S., et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41 (2005) 722-723
18. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005) 2654-2666
19. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102 (2005) 18538-18543
20. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory cells in the peripheral blod of cancer patients. Clin Cancer Res 9 (2003) 606-612
21. + regulatory T cells in patients with gastrointestinal malignancies. Possible involvement of regulatory cells in disease progression. Cancer 98 (2003) 108-109
22. + T cells in tumors from patients with early stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61 (2001) 4766-4772
23. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cels in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
24. Ormandy L.A., Hilleman T., Wedemeyer H., Manns M.P., Greten T.F., and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65 (2005) 2457-2462
25. Unitt E., Rushbrook S.M., Marshall A., Davies S., Gibbs P., Moris L.S., et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41 (2005) 722-730
26. + T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006) 3639-3646
27. +CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173 (2004) 1444-1453
28. Parmiani G. Tumor-infiltrating T cells - friend or foe of neoplastic cells?. N Engl J Med (2005) 2640-2641
29. Jones E., Dahm-Vicker M., Simon A., Green A., Powrie F., Cerundolo V., et al. Depletion of CD25* regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2 (2002) 1-12
30. Pages F., and Galon J. Immune cells in colorectal cancer. N Engl J Med 354 (2005) 1531-1532
31. Liu Y., Poon R.T., Hughes J., Feng X., Yu W.C., and Fan S.T. Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. Clin Immunol 114 (2005) 174-182
32. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100 (2003) 10902-10906
33. + T cells during chronic hepatitis C virus infection. J Virol 79 (2005) 7860-7867
34. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 (2005) 771-778
35. Bowen D.G., McCaugham G.W., and Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol 26 (2005) 512-517
36. Terabe M., Matsui S., Park J.-M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 (2003) 1741-1752
37. Clemente G.C., Mihm M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
38. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., and Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (2005) e284
39. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancev D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3636
40. Kuang M., Peng B.G., Lu M.D., Liang L.J., Huang J.F., He Q., et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for post-surgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10 (2004) 1574-1579